Cargando…

A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy

Bevacizumab plus chemotherapy is a well-established first-line treatment for metastatic colorectal cancer (mCRC). We investigated whether polymorphisms of genes involved in immune regulation signaling are related to the clinical outcome of mCRC patients treated with bevacizumab-based chemotherapy. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Wan, Zhao, Ben, Wang, Duanrui, Liu, Jiamin, Zhou, Yilu, Zhu, Wenjun, Huang, Yongbiao, Qiu, Hong, Yuan, Xianglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275392/
https://www.ncbi.nlm.nih.gov/pubmed/35837092
http://dx.doi.org/10.3389/fonc.2022.922342
_version_ 1784745476596170752
author Qin, Wan
Zhao, Ben
Wang, Duanrui
Liu, Jiamin
Zhou, Yilu
Zhu, Wenjun
Huang, Yongbiao
Qiu, Hong
Yuan, Xianglin
author_facet Qin, Wan
Zhao, Ben
Wang, Duanrui
Liu, Jiamin
Zhou, Yilu
Zhu, Wenjun
Huang, Yongbiao
Qiu, Hong
Yuan, Xianglin
author_sort Qin, Wan
collection PubMed
description Bevacizumab plus chemotherapy is a well-established first-line treatment for metastatic colorectal cancer (mCRC). We investigated whether polymorphisms of genes involved in immune regulation signaling are related to the clinical outcome of mCRC patients treated with bevacizumab-based chemotherapy. In this study, we genotyped 14 single-nucleotide polymorphisms (SNP) in IFN-γ/IFNGRs/JAKs/STATs/PD-L1 pathway by using DNA from blood samples of 141 mCRC patients treated with first-line bevacizumab-based chemotherapy. In the univariate and multivariate analysis, patients with AA genotype of CD274:rs2297136 had a significantly better PFS and OS than patients with AG or GG genotype (10.8 versus 9.8, log-rank P=0.0031; 31.4 versus 20.9, log-rank P=0.0233). Patients with AG/GG genotype of IFNGR1:rs2234711, CT/TT genotype of IFNGR1:rs9376267 also showed longer OS than patients with AA or CC genotype, however, the statistic did not reach significant after adjusted by clinical factors in the multivariate analysis. A nomogram based on the genetic variants and clinic characteristics was developed with a good accuracy to predict patients’ survival. Our result indicates that CD274:rs2297136 is one of the most important predictors for the prognosis of mCRC patients treated with bevacizumab-based chemotherapy, if further validated in larger population.
format Online
Article
Text
id pubmed-9275392
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92753922022-07-13 A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy Qin, Wan Zhao, Ben Wang, Duanrui Liu, Jiamin Zhou, Yilu Zhu, Wenjun Huang, Yongbiao Qiu, Hong Yuan, Xianglin Front Oncol Oncology Bevacizumab plus chemotherapy is a well-established first-line treatment for metastatic colorectal cancer (mCRC). We investigated whether polymorphisms of genes involved in immune regulation signaling are related to the clinical outcome of mCRC patients treated with bevacizumab-based chemotherapy. In this study, we genotyped 14 single-nucleotide polymorphisms (SNP) in IFN-γ/IFNGRs/JAKs/STATs/PD-L1 pathway by using DNA from blood samples of 141 mCRC patients treated with first-line bevacizumab-based chemotherapy. In the univariate and multivariate analysis, patients with AA genotype of CD274:rs2297136 had a significantly better PFS and OS than patients with AG or GG genotype (10.8 versus 9.8, log-rank P=0.0031; 31.4 versus 20.9, log-rank P=0.0233). Patients with AG/GG genotype of IFNGR1:rs2234711, CT/TT genotype of IFNGR1:rs9376267 also showed longer OS than patients with AA or CC genotype, however, the statistic did not reach significant after adjusted by clinical factors in the multivariate analysis. A nomogram based on the genetic variants and clinic characteristics was developed with a good accuracy to predict patients’ survival. Our result indicates that CD274:rs2297136 is one of the most important predictors for the prognosis of mCRC patients treated with bevacizumab-based chemotherapy, if further validated in larger population. Frontiers Media S.A. 2022-06-28 /pmc/articles/PMC9275392/ /pubmed/35837092 http://dx.doi.org/10.3389/fonc.2022.922342 Text en Copyright © 2022 Qin, Zhao, Wang, Liu, Zhou, Zhu, Huang, Qiu and Yuan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Qin, Wan
Zhao, Ben
Wang, Duanrui
Liu, Jiamin
Zhou, Yilu
Zhu, Wenjun
Huang, Yongbiao
Qiu, Hong
Yuan, Xianglin
A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy
title A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy
title_full A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy
title_fullStr A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy
title_full_unstemmed A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy
title_short A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy
title_sort genetic variant in cd274 is associated with prognosis in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275392/
https://www.ncbi.nlm.nih.gov/pubmed/35837092
http://dx.doi.org/10.3389/fonc.2022.922342
work_keys_str_mv AT qinwan ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT zhaoben ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT wangduanrui ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT liujiamin ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT zhouyilu ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT zhuwenjun ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT huangyongbiao ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT qiuhong ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT yuanxianglin ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT qinwan geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT zhaoben geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT wangduanrui geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT liujiamin geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT zhouyilu geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT zhuwenjun geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT huangyongbiao geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT qiuhong geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy
AT yuanxianglin geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy